Antonella Iacoviello

Mrs. Antonella Iacoviello

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2025 in Cancers
Verified
Journal Article
Open access
PDF file
LTLidia Tarone
Lidia Tarone
AIAntonella Iacoviello
Antonella Iacoviello
ALAntonino Di Lorenzo
Antonino Di Lorenzo
RVRoberta Verta
Roberta Verta
CCChiara Cossu
Chiara Cossu
FRFederica Riccardo
Federica Riccardo
Osteosarcoma (OSA) is an aggressive primary bone cancer mainly affecting the pediatric population. Despite intensive multimodal treatments, therapeutic progress has remained limited for decades, resulting in high recurrence rates, poor prognosis driven by metastatic progression, and severe chemotherapy-associated toxicities. To advance the development of more effective and safer therapeutic strategies, our recent studies identified Chondroitin Sulfate Proteoglycan (CSPG)4 as a relevant mediator of the malignant behavior of OSA cells. Targeting CSPG4 DNA-based vaccine demonstrated encouraging antitumor activity against OSA. Nevertheless, since single-agent immunotherapies are often constrained by tumor immune escape, the need for rational combinatorial strategies is of utmost importance. In this perspective, we broaden our analysis to include other potentially complementary targets beyond CSPG4, which may contribute to OSA pathogenesis. Among these, the cystine/glutamate antiporter xCT and Toll-like Receptor 2 (TLR2) emerge as particularly promising due to their established role in tumor progression, therapy resistance, and immune modulation. We discuss the contribution of all these molecules in major hallmarks of OSA—(1) proliferative and survival advantages, (2) metastasis and angiogenesis, and (3) immune evasion—and examine potential strategies for their combined targeting. By leveraging knowledge gained from other cancer models and integrating it with the distinct biological and clinical features of OSA, this perspective seeks to outline rational and innovative combinatorial strategies that may overcome current therapeutic limitations and ultimately improve patient outcomes.

1 February 2026 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
ALAntonino Di Lorenzo
Antonino Di Lorenzo
CRChiara Romiti
Chiara Romiti
AAAlessandro Amaolo
Alessandro Amaolo
CCChiara Cossu
Chiara Cossu
AIAntonella Iacoviello
Antonella Iacoviello
LAURA CONTILAURA CONTI
LAURA CONTI
Purpose: Breast cancer remains the leading cause of cancer-related death in women, largely due to therapy resistance driven by both tumor-intrinsic and tumor microenvironment (TME)-mediated mechanisms. Toll-like receptor 2 (TLR2), which is overexpressed in breast tumors, promotes cancer progression and chemoresistance through both cancer-cell intrinsic and immune-mediated signaling, making it a promising therapeutic target. Methods: We developed a targeted therapy combining two types of nanoparticles (NPs) for targeted drug delivery, hybrid poly (lactic-co-glycolic acid) (PLGA)- lipid NPs loaded with the TLR2 inhibitor CU-CPT22 (PLGA-CU) and liposomes encapsulating doxorubicin (LIPO-DOXO). Both NP types were functionalized with cyclic RGD peptides to target αvβ3 integrins. Their effects were evaluated in vitro on triple-negative and HER2-positive breast cancer cells and in vivo in 4T1 triple negative breast cancer tumor-bearing mice. Results: PLGA-CU effectively inhibited TLR2 signaling. Both PLGA-CU and LIPO-DOXO reduced cell viability and induced apoptosis, with stronger effects observed when used in combination. In vivo imaging confirmed the accumulation of NPs in tumors. While monotherapies reduced tumor growth, the combined treatment targeted both cancer cells and TME, leading to reduced angiogenesis and immunosuppression, as well as enhanced anti-tumor activity. Conclusion: NP-mediated delivery of a TLR2 inhibitor and doxorubicin produces synergistic anti-cancer effects in breast cancer models. This approach may help overcome chemoresistance and improve therapeutic outcomes, offering a promising strategy for the treatment of advanced breast cancer.